×
About 34,850 results

ALLMedicine™ Gastric Cancer Center

Research & Reviews  13,014 results

Evaluation of dual-energy CT derived radiomics signatures in predicting outcomes in pat...
https://doi.org/10.1016/j.ejso.2021.07.014
European Journal of Surgical Oncology : the Journal of Th... Chen Y, Yuan F et. al.

Jul 26th, 2021 - To investigate the prognostic value of dual-energy CT (DECT) based radiomics to predict disease-free survival (DFS) and overall survival (OS) for patients with advanced gastric cancer (AGC) after neoadjuvant chemotherapy (NAC). From January 2014 t...

A Preclinical Human-Derived Autologous Gastric Cancer Organoid/Immune Cell Co-Culture M...
https://doi.org/10.3791/61443
Journal of Visualized Experiments : JoVE; Chakrabarti J, Koh V et. al.

Jul 26th, 2021 - Tumors expressing programmed cell death-ligand 1 (PD-L1) interact with programmed cell death protein 1 (PD-1) on CD8+ cytotoxic T lymphocytes (CTLs) to evade immune surveillance leading to the inhibition of CTL proliferation, survival, and effecto...

Global Incidence and Mortality of Gastric Cancer, 1980-2018.
https://doi.org/10.1001/jamanetworkopen.2021.18457
JAMA Network Open; Wong MCS, Huang J et. al.

Jul 26th, 2021 - Gastric cancer is one of the most common cancers, with a high mortality-to-incidence ratio. It is uncertain whether developed nations may encounter an increasing burden of gastric cancer in young adults, as occurs for other cancers. To evaluate th...

ASO Authors Reflection: N3 Stage Gastric Cancer Needs Treatment Intensification.
https://doi.org/10.1245/s10434-021-10510-3 10.1007/s11605-016-3197-9 10.1016/S0140-6736(18)32557-1 10.1002/jso.23325 10.1016/j.annonc.2020.11.017
Annals of Surgical Oncology; Bhandare MS, Pachaury A et. al.

Jul 26th, 2021 - ASO Authors Reflection: N3 Stage Gastric Cancer Needs Treatment Intensification.|2021|Bhandare MS,Pachaury A,Chaudhari V,Shrikhande SV,|

Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer...
https://doi.org/10.1007/s12032-021-01549-z 10.3322/caac.21492 10.1200/JCO.2011.36.5908 10.1002/jso.23301 10.1002/bjs.9484 10.1093/annonc/mdu472 10.1097/01.sla.0000133083.54934.ae 10.1007/s10120-020-01136-7 10.1007/s00595-015-1276-2 10.1136/esmoopen-2016-000130 10.1200/JCO.2005.01.305 10.1016/j.ejca.2017.11.020 10.1093/annonc/mdx236 10.1245/s10434-013-3055-x
Medical Oncology (Northwood, London, England); Serizawa A, Kuramochi H et. al.

Jul 24th, 2021 - In Japan, the standard treatment for stage II or III gastric cancer is D2 gastrectomy followed by administration of S-1 for one year. However, patients with stage III disease have unsatisfactory survival rates. The purpose of this study was to eva...

see more →

Guidelines  20 results

Hereditary diffuse gastric cancer: updated clinical practice guidelines.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116190
The Lancet. Oncology; Blair VR, McLeod M et. al.

Aug 7th, 2020 - Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome that is characterised by a high prevalence of diffuse gastric cancer and lobular breast cancer. It is largely caused by inactivating germline mutations in the tumour...

Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION, Number 793.
https://doi.org/10.1097/AOG.0000000000003562
Obstetrics and Gynecology;

Nov 25th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheri...

British Society of Gastroenterology guidelines on the diagnosis and management of patie...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709778
Gut Banks M, Graham D et. al.

Jul 6th, 2019 - Gastric adenocarcinoma carries a poor prognosis, in part due to the late stage of diagnosis. Risk factors include Helicobacter pylori infection, family history of gastric cancer-in particular, hereditary diffuse gastric cancer and pernicious anaem...

ACG and CAG Clinical Guideline: Management of Dyspepsia.
https://doi.org/10.1038/ajg.2017.154
The American Journal of Gastroenterology; Moayyedi P, Lacy BE et. al.

Jun 20th, 2017 - We have updated both the American College of Gastroenterology (ACG) and the Canadian Association of Gastroenterology (CAG) guidelines on dyspepsia in a joint ACG/CAG dyspepsia guideline. We suggest that patients ≥60 years of age presenting with dy...

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
https://doi.org/10.1038/ajg.2016.563
The American Journal of Gastroenterology; Chey WD, Leontiadis GI et. al.

Jan 10th, 2017 - Helicobacter pylori (H. pylori) infection is a common worldwide infection that is an important cause of peptic ulcer disease and gastric cancer. H. pylori may also have a role in uninvestigated and functional dyspepsia, ulcer risk in patients taki...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  567 results

TEW-7197 With Paclitaxel for the Treatment of Metastatic Gastric Cancer
https://clinicaltrials.gov/ct2/show/NCT03698825

May 5th, 2020 - This is an open-label, single arm study evaluating the safety and tolerability of TEW-7197 in combination with paclitaxel in metastatic gastric cancer patients.

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
https://clinicaltrials.gov/ct2/show/NCT02554812

May 5th, 2020 - This is a Phase 1b/2, open-label, multi-center, multiple-dose, safety, clinical activity, PK, and PD study of avelumab in combination with other immune modulators in adult patients with locally advanced or metastatic solid tumors (eg, non-small ce...

Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)
https://clinicaltrials.gov/ct2/show/NCT03382600

Apr 30th, 2020 - Approximately 45 participants will be assigned first to pembrolizumab + oxaliplatin + TS-1 combination therapy (Cohort 1), and then 45 participants will be assigned to pembrolizumab + cisplatin + TS-1 combination therapy (Cohort 2).

Study of E7389 Liposomal Formulation in Subjects With Solid Tumor
https://clinicaltrials.gov/ct2/show/NCT03207672

Apr 27th, 2020 - The maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF) will be determined in the dose escalation part. Safety, pharmacokinetics (PK) and efficacy will be assessed using treatment regimen evaluated in dose escalation part in par...

Uncut Roux-en-Y vs Roux-en-Y
https://clinicaltrials.gov/ct2/show/NCT03349398

Apr 15th, 2020 - To search which is the better reconstructions by comparing and analyzing the advantages and disadvantages between Uncut Roux-en-Y and Roux-en-Y reconstructions after laparoscopy-assisted distal gastrectomy for gastric cancer. Method: It's a prospe...

see more →

News  333 results

First-Line H pylori Regimens Ranked by Comparative Effectiveness
https://www.medscape.com/viewarticle/954605

Jul 11th, 2021 - A network meta-analysis of current first-line dual, triple, and quadruple therapies for Helicobacter pylori infection found that vonoprazan triple therapy was most effective, while standard triple therapy of a proton pump inhibitor (PPI), amoxicil...

Metabolites in Plasma Could Serve as Biomarkers for Early Gastric Cancer
https://www.medscape.com/viewarticle/953939

Jun 29th, 2021 - NEW YORK (Reuters Health) - Decreased plasma metabolite levels show promise as noninvasive biomarkers for early gastric cancer in high-risk populations, a new study from China suggests. "We found that a set of plasma metabolites - particularly alp...

Potential Predictive Biomarker for Paclitaxel Benefit in Gastric Cancer Identified
https://www.medscape.com/viewarticle/951944

May 27th, 2021 - NEW YORK (Reuters Health) - Using machine-learning techniques on data from a large gastric cancer trial, researchers have identified a potential biomarker of survival benefit from treatment with paclitaxel. "Applying machine-learning/artificial in...

Liver, Gastric Cancer Disparities Consistent Across Race and Ethnicity
https://www.medscape.com/viewarticle/951962

May 26th, 2021 - While colorectal cancer may be the most common and deadly gastrointestinal malignancy, liver and gastric cancers account for some of the most consistent racial and ethnic disparities, a recent retrospective, cross-sectional analysis of U.S. data s...

PPIs Associated With Gastric Cancer Regardless of H. Pylori Eradication Status
https://www.medscape.com/viewarticle/951571

May 20th, 2021 - (Reuters Health) - Taking proton pump inhibitors (PPIs) is associated with increased risk of developing gastric cancer regardless of Helicobacter pylori eradication status, a Korean study suggests. Researchers examined data in the Korean National ...

see more →

Patient Education  4 results see all →